RichardNChannickMD
Pulmonology • Los Angeles, CACritical Care Medicine
Associate Professor, Medicine-Massachusetts General Hospital, Harvard Medical School
Dr. Channick is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
10833 Le Conte Ave
Rm 37-131
Los Angeles, CA 90095- Is this information wrong?
Education & Training
University of California (San Diego) Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 1991
UMass Chan Medical SchoolResidency, Internal Medicine, 1984 - 1988
Lewis Katz School of Medicine at Temple UniversityClass of 1984
Certifications & Licensure
CA State Medical License 1988 - 2025
MA State Medical License 1986 - 2020- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Selexipag (ACT-293987) in Pulmonary Arterial Hypertension Start of enrollment: 2009 Dec 01
- Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER Start of enrollment: 2017 Apr 18
- Effect of iNO in Patients With Submassive and Massive PE Start of enrollment: 2021 Jun 01
Publications & Presentations
PubMed
- Atrial Arrhythmias in Patients With Pulmonary Hypertension.Kyle O'Meara, Gregory Stone, Eric Buch, Adam Brownstein, Rajan Saggar, Richard Channick, Alexander E Sherman, Aron Bender> ;Chest. 2024 Mar 5
- 1 citationsModelling Costs of Interventional Pulmonary Embolism Treatment: Implications of US Trends for a European Healthcare System.Mohr, K., Keeling, B., Kaier, K., Neusius, T., Rosovsky, R., Moriarty, J., Rosenfield, K., Abele, C., Farmakis, I., Keller, K., Barco, S., Channick, R., Giri, J., Look...> ;European Heart Journal. Acute Cardiovascular Care. 2024 Feb 13
- Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies.Kim, N., MacDonald, G., Martin, N., Rosenberg, D., Solonets, M., Chin, K., McLaughlin, V., DuBrock, H., Restrepo-Jaramillo, R., Safdar, Z., Channick, R.> ;Pulmonary Therapy. 2024 Mar 1
- Join now to see all
Lectures
- ACC-Talk: What are the Implications of the 6th World Symposium for the General Cardiologist?2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- What’s the Most Practical Approach to PAH Risk Stratification for the Clinician?2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
- Pulmonary and Critical Care MedicineHarvard Medical School ,Department Of Continuing Education, Cambridge, Massachusetts - 4/28/2013
Press Mentions
Pulmonary Embolism Treatment Teams Adopted Widely for Complex DiseaseNovember 20th, 2019
I'm Aware That I'm Rare: Richard Channick, MD (180)August 24th, 2018- I'm Aware That I'm Rare: Richard Channick, MDAugust 6th, 2018
- Join now to see all
Grant Support
- Ut-15 + Conventional Therapy In Pulmonary HypertensionNational Center For Research Resources2000–2002
- RO 47-0203 In Exercise Capacity, Hemodynamics And QOL Of Pulmonary HypertensionNational Center For Research Resources2000–2002
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
